Novo Nordisk rebrands to 'Novo,' unveils corporate changes as it fights for obesity market share
The Danish drugmaker called the changes the beginning of a new chapter for the company, which faces stiff competition from Eli Lilly.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the briefHow this story developed
2 reports over 7h 4m-
CNBC Top Stories You're reading this Novo Nordisk rebrands to 'Novo,' unveils corporate changes as it fights for obesity market share Neutral 0
-
Market Watch Novo Nordisk is changing its name and its culture to try to compete in the GLP-1 diet-drug wars Strong bearish −56

